The three tablets, Efavirenz, Emtricitabine and Tenofovir Disproxil Fumurate, known collectively as EET, have all seen approval as generic alternatives to Gilead’s Atripla. Credit: Shutterstock / PENpics Studio

Bangalore, India-based Strides Pharma Global has announced that it has received approval from the US Food and Drug Administration (FDA) to market three generic drugs intended to treat HIV.

The three tablets, efavirenz (600mg), emtricitabine (200mg), and tenofovir disproxil fumurate (300mg), known collectively as EET, have been approved as generic alternatives to Gilead Sciences’ Atripla.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The greenlight for the bioequivalent marks the 15th product developed by the firm, within the same therapeutic category, to see success through the US Government’s Emergency Plan for AIDS Relief’s (PEPFAR) pathway.

A spokesperson for Strides Pharma Global said: “The PEPFAR approval for Strides qualifies the company to participate in global donor-funded programs that procure this lifesaving medicine and it is supplied in around 10 countries.

“As of full year 2022, donor procurement for EET Tablets is estimated at a value of around 15 million USD. This product further strengthens the available offerings in HIV treatment from Strides.”

See Also:

The company has said that the drug has a market opportunity in the US of $7.5m. As per Global Data’s Pharmaceutical intelligence Centre the originator drug—Gilead’s Atripla—earned $121 million in revenues 2021, which was down from the previous year’s sales of $307 million.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Global Data is the parent company of Pharmaceutical Technology.

The drug is set to be manufactured at the company’s facility in Bengaluru. As a result of the announcement Shares of Strides Pharma Science jumped 2.51% to Rs 508.20 per stock.

Last year, Strides Pharma was able to enter a sub-license agreement with the Medicines Patent Pool (MPP) for the marketing of a generic version of Pfizer’s Covid-19 oral drug Paxlovid.